16 related articles for article (PubMed ID: 17655841)
1. Potassium Channels and Their Potential Roles in Substance Use Disorders.
McCoy MT; Jayanthi S; Cadet JL
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513859
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of morphine-induced antinociception by harmaline: involvement of μ-opioid and ventral tegmental area NMDA receptors.
Alijanpour S; Zarrindast MR
Psychopharmacology (Berl); 2020 Feb; 237(2):557-570. PubMed ID: 31740992
[TBL] [Abstract][Full Text] [Related]
3. Influence of ATP-dependent K+ channels on nicotine-induced inhibition of withdrawal in morphine-dependent mice.
Zarrindast MR; Mohajeri S
Eur J Pharmacol; 2006 Dec; 552(1-3):90-8. PubMed ID: 17049514
[TBL] [Abstract][Full Text] [Related]
4. Involvement of amlodipine, diazoxide, and glibenclamide in development of morphine tolerance in mice.
Khalilzadeh O; Anvari M; Khalilzadeh A; Sahebgharani M; Zarrindast MR
Int J Neurosci; 2008 Apr; 118(4):503-18. PubMed ID: 18322859
[TBL] [Abstract][Full Text] [Related]
5. Morphine sex-dependently induced place conditioning in adult Wistar rats.
Karami M; Zarrindast MR
Eur J Pharmacol; 2008 Mar; 582(1-3):78-87. PubMed ID: 18191832
[TBL] [Abstract][Full Text] [Related]
6. Morphine-induced place preference: involvement of cholinergic receptors of the ventral tegmental area.
Rezayof A; Nazari-Serenjeh F; Zarrindast MR; Sepehri H; Delphi L
Eur J Pharmacol; 2007 May; 562(1-2):92-102. PubMed ID: 17336285
[TBL] [Abstract][Full Text] [Related]
7. The involvement of K(ATP) channels in morphine-induced antinociception and hepatic oxidative stress in acute and inflammatory pain in rats.
Afify EA; Khedr MM; Omar AG; Nasser SA
Fundam Clin Pharmacol; 2013 Dec; 27(6):623-31. PubMed ID: 23033987
[TBL] [Abstract][Full Text] [Related]
8. Involvement of glucose and ATP-sensitive potassium (K+) channels on morphine-induced conditioned place preference.
Zarrindast MR; Sattari-Naeini M; Khalilzadeh A
Eur J Pharmacol; 2007 Nov; 573(1-3):133-8. PubMed ID: 17655841
[TBL] [Abstract][Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
